Cardiac Resynchronisation Therapy (CRT)Nordic-CSPNCT07492979
Conduction System Pacing vs. Biventricular Pacing for Cardiac Resynchronization Therapy
A study testing HIS or LBBB -CRT and Conventional BiV-CRT in people with Cardiac Resynchronisation Therapy (CRT) and Heart Failure, run by Copenhagen University Hospital, Rigshospitalet at 5 sites in 4 countries.
Trial summary
The NORDIC-CSP trial is an investigator-initiated, blinded, nordic RCT aimed at evaluating whether using direct pacing of the HIS bundle (HIS)-pacing or left bundle branch (LBB) pacing is superior to conventional biventricular pacing in reducing the incidence of the composite endpoint of death and non-planned HF… Read more about this study
- Who is it for?
- Ages 18 to 99 years
- Conditions the study is for
- Cardiac Resynchronisation Therapy (CRT), Heart Failure, Conduction System Pacing
- What is being tested?
- HIS or LBBB -CRT and Conventional BiV-CRT
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,100 participants
- Where
- 5 sitesin 4 countries
- Study dates
- 17 Jun 2026to 1 Jul 2031
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 99 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ≥18 years of age,
- LVEF ≤ 35%,
- NYHA Class II-IV (IV only outpatients),
- optimized in medical treatment (OMT)
- AND one of the following:
- . LBBB according to AHA/ACC/HRS Scientific Statement from 2009 and ≥130ms or
Show all 10Show fewer
- LBBB-like intraventricular conduction delay (IVCD) > 150ms or RV paced QRS and indication for upgrade to CRT (> 40% RV pacing) OR
- ≥18 years of age,
- LVEF ≤ 40 %
- pacing indicated by AV-block and, thus, expected large percentage of ventricular pacing.
Who cannot join
- recent acute myocardial infarction (AMI)
- coronary artery bypass graft (CABG) (<3 months)
- life expectancy <2 years, patients in hemodialysis
- treatment with a cardiac implantable electronic device (CIED) is contraindicated.
- Patients are excluded with regards to the MRI sub study if eGFR > 35 ml/min, in case or contrast allergy or certain metal implants.
Trial locations and contacts
5 sites in 4 countries. Contact the study team or a site near you to ask about taking part.
5 sites in 4 countries
Denmark2 sites, 2 recruiting
- Not yet recruiting
Dept. of Cardiology, Aarhus University Hospital, Aarhus
Aarhus, 8200
Jens Kristensen, MD, PhD, 0045 29410644, jens.kristensen@auh.rm.dk
- Recruiting
Rigshospitalet, Copenhagen University Hospital
Copenhagen, 2100
Niels Risum, MD, PhD, 004535456995, nordic-csp.rigshospitalet@regionh.dk
Michael vinther, MD, PhD, 004535456994, michael.vinther@regionh.dk
Finland1 site, 1 recruiting
- Not yet recruiting
Dept of Cardiology, Meilahti Hospital, Helsinki
Helsinki, 00290
Jarkko Karvonen Karvonen, jarkko.karvonen@hus.fi
Norway1 site, 1 recruiting
- Not yet recruiting
Haukeland Universitetssykehus
Bergen, 5009
Torbjørn Lunde, 0047 xxxxxxxx, torbjorn.lunde@gmail.com
Sweden1 site, 1 recruiting
- Not yet recruiting
Sahlgrenska University Hospital
Gothenburg
Amar Taha, 0046 313427551, Amar.taha@vregionh.se
About this study
Official title: Nordic-CSP - a Randomized Nordic Study - Is Conduction System Pacing Superior Compared to Conventional BIV-CRT in Reducing the Death or Heart Failure-related Hospitalization in Patients With Heart Failure and Bundle Branch Block?
The NORDIC-CSP trial is an investigator-initiated, blinded, nordic RCT aimed at evaluating whether using direct pacing of the HIS bundle (HIS)-pacing or left bundle branch (LBB) pacing is superior to conventional biventricular pacing in reducing the incidence of the composite endpoint of death and non-planned HF hospitalization. The study will be conducted in the 4 CRT-centres in Denmark and 6-8 centres from countries Sweden, Norway and Finland.
Read the detailed description
In this investigator-initiated, blinded, nordic RCT, we will investigate conduction system pacing (CSP) in heart failure (HF) patients. We hypothesized that Cardiac Resynchronization Therapy (CRT) by HIS-pacing or LBB-pacing is superior compared to conventional biventricular (BIV)-CRT in reducing the incidence of the composite endpoint (Death and HF-hospitalization) in patients with symptomatic HF, with LVEF ≤ 35% and indication for CRT.
The Study is a collaboration between CRT centers in the Nordic countries with experience in CSP.
Randomization:
Randomization is conducted electronically using the CRF on the day of device implantation. A computer algorithm will randomly assign patients 1:1 to either the conventional method BIV-CRT or to "the new method" HIS/LBB-CRT.
Randomization will be stratified by the presence of a) true LBBB, b) other bundle branch block (BBB) and c) RV pacing. This will be performed by randomizing in blocks of 10 for LBBB and RV pacing/other bundle branch blocks. Block-randomization is used to ensure that each center includes a similar number of patients for each treatment arm.
The implanting physician is aware of group allocation to provide the correct treatment. Only the implanting physician can access this information in the CRF. The patients and study per-sonnel involved in end-point adjudication as well as all personnel performing imaging analy-sis are blinded to randomization. Follow-up is identical in the two treatment groups. All fol-low-up personnel are blinded to treatment assignment.
Implantation:
The RV electrode is preferentially placed in an RV septal position unless factors related to lead stability, electrical values, and defibrillation vector favor an apical position (at the discretion of the implanting physician). The atrial electrode is positioned at the preference of the implanting physician. With successful implantation of a lead for HIS- or LBB-pacing the physician may prefer to not implant a RV-lead to the septum. In that case, there is no need for a CRT pacemaker and a dual-chamber pacemaker can be implanted instead.
In the HIS-LBB group, CSP is performed according to current recommendations13. The leads allowed to implant in the HIS-LBB position are the ones that have received CE-approval for this indication.
Both HIS-pacing or LBB-pacing can be attempted as first approach at the physician's discretion using available leads both stylet-driven or non-stylet driven and if necessary, guiding from an electrophysiology catheter is used.
HIS-pacing: An approximate ratio of 1:4 between A and V with a clear His deflection is iden-tified and His-capture confirmed. If the threshold for capture of His and the left bundle branches is too high (> 2 V at 1 ms duration) assessed by the operator, the lead should be replaced. If it is not possible to achieve selective or non-selective HIS pacing with bundle branch block correction at a threshold below or equal to 2 V at 1 ms in duration, an attempt to implant the electrode to achieve direct left bundle branch pacing (LBBP) is performed instead.
LBB-pacing: LBB-pacing is performed by moving the sheath a few centimeter further towards the apex of the right ventricle, ensuring contact to the septum. The electrode is screwed into the septum at an angle of -10⁰ to 40⁰ while monitoring current-of-injury (COI), impedance and pacing configuration (gradual emergence of a terminal R-wave in lead V1) until the left bundle branch area is activated and a right-sided bundle branch block pattern is obtained. The operator must attempt to confirm left conduction system capture by identify-ing one or more of the following criteria:
- Fixation beats (PVC´s identical to the paced QRS-complex,)
- Identification of LBB-potentials (> 15 ms before sensed QRS) and capture with RBBB-pattern during unipolar pacing on the LBB-lead. (Not in LBBB patients)
- Transition of QRS patterns during threshold testing: ns-LBBP to s-LBBP : splitting of EGM and/or V1 RWPT (Rigth wave peak time)¬ by > 10 ms ns-LBBP to LVSP : V6 RWPT¬ by ≥ 15 ms V6 RWPT < 80 ms (LBBB, IVCD RBBB+fascicular block, wide escape rhythm, asystole) V6 -V1 interpeak interval > 44 ms QRS transition to s-LBBP during programmed stimulation
Or one of the following criteria considered likely to represent left conduction system capture:
V6 RWPT < 100 ms (LBBB, IVCD, RBBB + fascicular block, wide escape rhythm, asystole V6 -V1 interpeak interval > 33 ms QRS transition to LVSP during programmed stimulation V6 RWPT prolongation by 10-14 ms during threshold test
If the operator is not succesful, after several attempts, obtaining conduction system capture LVseptal capture (LVSP) can be accepted, with identification of a clearly defined R´ in V1. If only deep septal pacing can be obtained the lead can be left in place or removed at the op-erators discretion and an LV-lead has to be implanted to obtain either BIV-CRT or LOT-CRT.
.
Cross-over between intervention arms If neither HIS-pacing nor LBB-pacing is obtainable (none of the abovementioned criteria are met or Left Ventricular septal pacing cannot be obtained), the sheath is switched to a CS sheath instead and an LV electrode is placed as in a conventional CRT procedure. Finally, an atrial electrode is placed if there is not already a usable atrial electrode in place. In all pa-tients, signs of left conduction system capture identified are registered in the CRF.
In the BIV-CRT group, the LV lead is placed in the branch judged to be most suitable, prefer-entially in a posterolateral (2-5 o'clock in the mitral annulus), and mid-ventricular or basal, non-apical position (figure 2), after taking into consideration lead stability, pacing threshold and threshold for phrenic nerve stimulation. In general, multipolar (quadripolar) LV leads are used as first choice but the implanting physician may use a bipolar LV lead if a multipolar lead cannot be implanted. Balloon occlusion venography to visualize the CS and side branches is performed in all patients with a BIV-CRT. Supplementary selective venography may be used to visualize CS branches.
If it is not possible to place a LV -lead due to the anatomical conditions (lack of access to CS, lack of available side bundle branches or only possible to pace in the vena cordis media or vena cordis anterior) or due to unacceptable electrical measurements (best pacing threshold > 4 V at 1,0 msec, or phrenic nerve capture < 2 x lowest pacing threshold), the sheath is in-stead switched to a HIS sheath and electrode placement to the HIS bundle or LBB area is attempted using available sheaths and guide from electrophysiology catheter as outlined above. Again, it is up to the physician whether HIS- or LBB-pacing is attempted first. If it is not possible to achieve selective or non-selective HIS pacing with bundle branch block cor-rection at a threshold below or equal to 2.5 V at 1 ms in duration, an attempt is done to im-plant the electrode further into the ventricle and achieve direct left bundle branch pacing (LBB-CRT) instead. Finally, an atrial electrode is placed if there is not already a usable atrial lead in place. If it is not possible to place either an LV electrode, a HIS electrode or an elec-trode for LBB pacing, the attending physician must decide whether there is any indication for implantation of a transthoracic LV-lead.
Follow-up:
Clinical- and device check-ups are scheduled after 3-, 6- and 12 months, and annually thereafter according .This means that patients are in fact following the current standard regime after CRT-implantation with similar examinations including standard blood tests. However, in addition the patients will be asked to fill out questionnaires, that is the MLHFQ and PRO Questionnaires at baseline and 12 months. Remote monitoring is established for all pa-tients. Echocardiographic follow-ups are scheduled after 6- and 24 months. A 6MWT is per-formed 6 months. At each follow-up visit, medication is recorded and a ECG-12 is obtained upon patient arrival.
All patients are followed for a minimum of 2 years.
- Being tested
- HIS or LBBB -CRT, Conventional BiV-CRT
- Keywords
- Nordic-CSP, conduction system pacing, His-pacing, LBB-pacing, Biventricular pacing, Cardiac Resynchronization Therapy
- Medical subject headings
- Heart Failure
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
HIS or LBBB -CRTProcedure or surgery
HIs pacing og LBB pacing at the implanteres discretion
Conventional BiV-CRTProcedure or surgery
An LV-lead in a side-branch of the coronary sinus
| Study group | Role | What they receive |
|---|---|---|
| LBB/HIS-CRT group | Experimental | Not described Receives: Procedure: HIS or LBBB -CRT |
| BiV-CRT group | Experimental | Not described Receives: Procedure: Conventional BiV-CRT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patients with a primary end-point
The primary endpoint is a composite of time to death or first non-planned HF hospitalization. Non-planned HF is defined as an unplanned emergency room visit or admission to hospital due to worsening HF
Measured: From enrollment and a minimum of 2 years or the primary outcome has occurred
Secondary outcomes (17)
Patients experiencing device-related complications
- Device-related complications. Periprocedural complication including electrode reoperation, pneumothorax, hemothorax, pericardial bleeding/tamponade and later complications (after 30 days post implantation) including LV/His electrode reoperation, change of device due to battery depletion and infection requiring extraction.
Measured: From baseline until study completion, with a minimum of 2 years.
Death
All-cause death
Measured: From baseline until study completion, with a minimum of 2 years
Non planned HF-hospitalization
Non-planned HF is defined as an unplanned emergency room visit or admission to hospital due to worsening HF
Measured: From baseline until study completion with a minimum of 2 years
Echocardiographic remodelling
Echocardiographic end-points (re-modelling of the LV measured in mL: LVESV, LVEDV, LVEF). Echocardiographic response after 6 months and 24 months defined as decrease in left ventricular systolic volume ≥ 15% from baseline.
Measured: From baseline to 6 months and 24 months
Change in Dyssynchrony
Change in dyssynchrony parameters myocardial work, longitudinal strain time-to-peak (ms), dyssynchrony patterns (categorized 1-4), apical rocking, septal flash (yes/No)
Measured: evaluated at baseline, 6 months, 24 months
Improvement in Clinical response
Clinical response improvement in NYHA class by ≥ 1 or improvement in 6MWT (≥10% from baseline)" after 12 months.
Measured: from baseline to 12 months
Improvement in Six-min walking test.
Functional response after 6 months defined as an increase in 6-min walking distance (meters) of ≥ 20% of the baseline value
Measured: From baseline to 6 months
Neurohormones
Neurohormones, decline in NT-proBNP after CRT. pg/mL (picograms per milliliter) or ng/L (nanograms per liter)
Measured: from baseline to 6 months
Symptomatic response
defined as a fall in NYHA class of ≥ 1
Measured: From baseline to 6 months
Life quality
Minnesota Living with Heart Failure Qestionnaire. Comparison from baseline to 12 months follow-up in point score (0-105).
Number of patients with improvements > 5 points and above 10 points are determined.
Measured: from baseline to follow-up at 12 months
ICD therapy
ICD-therapy (time to first) of appropriate and inappropriate therapies, ATP or Shock
Measured: from baseline to study completion, with a mnimum of 2 years
Ventricular arrythmia
Time to first VT (>135/min by ecg or device reading) or VF
Measured: from baseline to completion of the study, with a mnimum of 2 years
atrial fibrillation
time to Persistent atrial fibrillation (> 7 days) and new-onset atrial fibrilllation (> 6 hours)
Measured: from baseline to completion of the study with a minimum of 2 years
time for implantation
measured in minutes from skin incision to skin closure
Measured: at implantation, from 30 minutes to 300 minutes
x-ray
- Use of X-ray dosage
Measured: at implantation, from 1 minute to 150 minutes
Electrodes
number of electrodes used
Measured: form implantation to completion of the study, a minimum of 2 years
battery longevity
- Battery longevity: The total battery longevity of each CRT-D was calculated as the sum of the patient's follow-up duration plus the estimated battery longevity remaining at the time of the last follow-up.
Measured: from implantation to completion of the study, with a minimum of 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Mar 2026
- Study start17 Jun 2026
- Primary completion1 Mar 2031 (estimated)
- Study completion1 Jul 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac Resynchronisation Therapy (CRT)Studies of the same condition, open and under way.
- More trials run by Copenhagen University Hospital, RigshospitaletThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 1,100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Copenhagen University Hospital, Rigshospitalet
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Niels Risum, Copenhagen University Hospital, Rigshospitalet
- Investigators
- Niels Risum Risum, MD, PhD, Principal investigator, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmarkmichael vinther, MD, PhD, Principal investigator, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkBerit Philbert, Study chair, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07492979
- Sponsor's protocol ID
- 119231
- Acronym
- Nordic-CSP
- Status last verified
- Jul 2026
- First submitted
- 10 Feb 2026
- Last updated
- 28 Jul 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: not yet a plan for this
Study at a glance
From the registry record, last updated by the sponsor on 28 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Nordic-CSP - a Randomized Nordic Study - Is Conduction System Pacing Superior Compared to Conventional BIV-CRT in Reducing the Death or Heart Failure-related Hospitalization in Patients With Heart Failure and Bundle Branch Block?
- ClinicalTrials.gov ID
- NCT07492979
- Acronym / sponsor ID
- Nordic-CSP / 119231
- Keywords
- Nordic-CSP, conduction system pacing, His-pacing, LBB-pacing, Biventricular pacing, Cardiac Resynchronization Therapy
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 1,100 participants (estimated)
- Lead sponsor
- Copenhagen University Hospital, RigshospitaletUniversity, hospital or other
- Study start
- 17 Jun 2026 (actual)
- Primary completion
- 1 Mar 2031 (estimated)
- Study completion
- 1 Jul 2031 (estimated)
- First posted
- 25 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The NORDIC-CSP trial is an investigator-initiated, blinded, nordic RCT aimed at evaluating whether using direct pacing of the HIS bundle (HIS)-pacing or left bundle branch (LBB) pacing is superior to conventional biventricular pacing in reducing the incidence of the composite endpoint of death and non-planned HF hospitalization. The study will be conducted in the 4 CRT-centres in Denmark and 6-8 centres from countries Sweden, Norway and Finland.
Detailed description
In this investigator-initiated, blinded, nordic RCT, we will investigate conduction system pacing (CSP) in heart failure (HF) patients. We hypothesized that Cardiac Resynchronization Therapy (CRT) by HIS-pacing or LBB-pacing is superior compared to conventional biventricular (BIV)-CRT in reducing the incidence of the composite endpoint (Death and HF-hospitalization) in patients with symptomatic HF, with LVEF ≤ 35% and indication for CRT.
The Study is a collaboration between CRT centers in the Nordic countries with experience in CSP.
Randomization:
Randomization is conducted electronically using the CRF on the day of device implantation. A computer algorithm will randomly assign patients 1:1 to either the conventional method BIV-CRT or to "the new method" HIS/LBB-CRT.
Randomization will be stratified by the presence of a) true LBBB, b) other bundle branch block (BBB) and c) RV pacing. This will be performed by randomizing in blocks of 10 for LBBB and RV pacing/other bundle branch blocks. Block-randomization is used to ensure that each center includes a similar number of patients for each treatment arm.
The implanting physician is aware of group allocation to provide the correct treatment. Only the implanting physician can access this information in the CRF. The patients and study per-sonnel involved in end-point adjudication as well as all personnel performing imaging analy-sis are blinded to randomization. Follow-up is identical in the two treatment groups. All fol-low-up personnel are blinded to treatment assignment.
Implantation:
The RV electrode is preferentially placed in an RV septal position unless factors related to lead stability, electrical values, and defibrillation vector favor an apical position (at the discretion of the implanting physician). The atrial electrode is positioned at the preference of the implanting physician. With successful implantation of a lead for HIS- or LBB-pacing the physician may prefer to not implant a RV-lead to the septum. In that case, there is no need for a CRT pacemaker and a dual-chamber pacemaker can be implanted instead.
In the HIS-LBB group, CSP is performed according to current recommendations13. The leads allowed to implant in the HIS-LBB position are the ones that have received CE-approval for this indication.
Both HIS-pacing or LBB-pacing can be attempted as first approach at the physician's discretion using available leads both stylet-driven or non-stylet driven and if necessary, guiding from an electrophysiology catheter is used.
HIS-pacing: An approximate ratio of 1:4 between A and V with a clear His deflection is iden-tified and His-capture confirmed. If the threshold for capture of His and the left bundle branches is too high (> 2 V at 1 ms duration) assessed by the operator, the lead should be replaced. If it is not possible to achieve selective or non-selective HIS pacing with bundle branch block correction at a threshold below or equal to 2 V at 1 ms in duration, an attempt to implant the electrode to achieve direct left bundle branch pacing (LBBP) is performed instead.
LBB-pacing: LBB-pacing is performed by moving the sheath a few centimeter further towards the apex of the right ventricle, ensuring contact to the septum. The electrode is screwed into the septum at an angle of -10⁰ to 40⁰ while monitoring current-of-injury (COI), impedance and pacing configuration (gradual emergence of a terminal R-wave in lead V1) until the left bundle branch area is activated and a right-sided bundle branch block pattern is obtained. The operator must attempt to confirm left conduction system capture by identify-ing one or more of the following criteria:
- Fixation beats (PVC´s identical to the paced QRS-complex,)
- Identification of LBB-potentials (> 15 ms before sensed QRS) and capture with RBBB-pattern during unipolar pacing on the LBB-lead. (Not in LBBB patients)
- Transition of QRS patterns during threshold testing: ns-LBBP to s-LBBP : splitting of EGM and/or V1 RWPT (Rigth wave peak time)¬ by > 10 ms ns-LBBP to LVSP : V6 RWPT¬ by ≥ 15 ms V6 RWPT < 80 ms (LBBB, IVCD RBBB+fascicular block, wide escape rhythm, asystole) V6 -V1 interpeak interval > 44 ms QRS transition to s-LBBP during programmed stimulation
Or one of the following criteria considered likely to represent left conduction system capture:
V6 RWPT < 100 ms (LBBB, IVCD, RBBB + fascicular block, wide escape rhythm, asystole V6 -V1 interpeak interval > 33 ms QRS transition to LVSP during programmed stimulation V6 RWPT prolongation by 10-14 ms during threshold test
If the operator is not succesful, after several attempts, obtaining conduction system capture LVseptal capture (LVSP) can be accepted, with identification of a clearly defined R´ in V1. If only deep septal pacing can be obtained the lead can be left in place or removed at the op-erators discretion and an LV-lead has to be implanted to obtain either BIV-CRT or LOT-CRT.
.
Cross-over between intervention arms If neither HIS-pacing nor LBB-pacing is obtainable (none of the abovementioned criteria are met or Left Ventricular septal pacing cannot be obtained), the sheath is switched to a CS sheath instead and an LV electrode is placed as in a conventional CRT procedure. Finally, an atrial electrode is placed if there is not already a usable atrial electrode in place. In all pa-tients, signs of left conduction system capture identified are registered in the CRF.
In the BIV-CRT group, the LV lead is placed in the branch judged to be most suitable, prefer-entially in a posterolateral (2-5 o'clock in the mitral annulus), and mid-ventricular or basal, non-apical position (figure 2), after taking into consideration lead stability, pacing threshold and threshold for phrenic nerve stimulation. In general, multipolar (quadripolar) LV leads are used as first choice but the implanting physician may use a bipolar LV lead if a multipolar lead cannot be implanted. Balloon occlusion venography to visualize the CS and side branches is performed in all patients with a BIV-CRT. Supplementary selective venography may be used to visualize CS branches.
If it is not possible to place a LV -lead due to the anatomical conditions (lack of access to CS, lack of available side bundle branches or only possible to pace in the vena cordis media or vena cordis anterior) or due to unacceptable electrical measurements (best pacing threshold > 4 V at 1,0 msec, or phrenic nerve capture < 2 x lowest pacing threshold), the sheath is in-stead switched to a HIS sheath and electrode placement to the HIS bundle or LBB area is attempted using available sheaths and guide from electrophysiology catheter as outlined above. Again, it is up to the physician whether HIS- or LBB-pacing is attempted first. If it is not possible to achieve selective or non-selective HIS pacing with bundle branch block cor-rection at a threshold below or equal to 2.5 V at 1 ms in duration, an attempt is done to im-plant the electrode further into the ventricle and achieve direct left bundle branch pacing (LBB-CRT) instead. Finally, an atrial electrode is placed if there is not already a usable atrial lead in place. If it is not possible to place either an LV electrode, a HIS electrode or an elec-trode for LBB pacing, the attending physician must decide whether there is any indication for implantation of a transthoracic LV-lead.
Follow-up:
Clinical- and device check-ups are scheduled after 3-, 6- and 12 months, and annually thereafter according .This means that patients are in fact following the current standard regime after CRT-implantation with similar examinations including standard blood tests. However, in addition the patients will be asked to fill out questionnaires, that is the MLHFQ and PRO Questionnaires at baseline and 12 months. Remote monitoring is established for all pa-tients. Echocardiographic follow-ups are scheduled after 6- and 24 months. A 6MWT is per-formed 6 months. At each follow-up visit, medication is recorded and a ECG-12 is obtained upon patient arrival.
All patients are followed for a minimum of 2 years.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| LBB/HIS-CRT group | Experimental | Procedure: HIS or LBBB -CRT |
| BiV-CRT group | Experimental | Procedure: Conventional BiV-CRT |
Who may qualify
- Ages
- 18 to 99 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (10 listed)
- ≥18 years of age,
- LVEF ≤ 35%,
- NYHA Class II-IV (IV only outpatients),
- optimized in medical treatment (OMT)
- . LBBB according to AHA/ACC/HRS Scientific Statement from 2009 and ≥130ms or
Key exclusion criteria (5 listed)
- recent acute myocardial infarction (AMI)
- coronary artery bypass graft (CABG) (<3 months)
- life expectancy <2 years, patients in hemodialysis
- treatment with a cardiac implantable electronic device (CIED) is contraindicated.
- Patients are excluded with regards to the MRI sub study if eGFR > 35 ml/min, in case or contrast allergy or certain metal implants.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| HIS or LBBB -CRTHIs pacing og LBB pacing at the implanteres discretion | Procedure or surgery | LBB/HIS-CRT group |
| Conventional BiV-CRTAn LV-lead in a side-branch of the coronary sinus | Procedure or surgery | BiV-CRT group |
Primary outcome
Patients with a primary end-point
Time frame: From enrollment and a minimum of 2 years or the primary outcome has occurred
The primary endpoint is a composite of time to death or first non-planned HF hospitalization. Non-planned HF is defined as an unplanned emergency room visit or admission to hospital due to worsening HF
17 secondary outcomes
Patients experiencing device-related complications
Time frame: From baseline until study completion, with a minimum of 2 years.
Death
Time frame: From baseline until study completion, with a minimum of 2 years
Non planned HF-hospitalization
Time frame: From baseline until study completion with a minimum of 2 years
Echocardiographic remodelling
Time frame: From baseline to 6 months and 24 months
Change in Dyssynchrony
Time frame: evaluated at baseline, 6 months, 24 months
Improvement in Clinical response
Time frame: from baseline to 12 months
Improvement in Six-min walking test.
Time frame: From baseline to 6 months
Neurohormones
Time frame: from baseline to 6 months
Symptomatic response
Time frame: From baseline to 6 months
Life quality
Time frame: from baseline to follow-up at 12 months
ICD therapy
Time frame: from baseline to study completion, with a mnimum of 2 years
Ventricular arrythmia
Time frame: from baseline to completion of the study, with a mnimum of 2 years
atrial fibrillation
Time frame: from baseline to completion of the study with a minimum of 2 years
time for implantation
Time frame: at implantation, from 30 minutes to 300 minutes
x-ray
Time frame: at implantation, from 1 minute to 150 minutes
Electrodes
Time frame: form implantation to completion of the study, a minimum of 2 years
battery longevity
Time frame: from implantation to completion of the study, with a minimum of 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Jul 2026.
- Individual participant dataSharing planned: No. not yet a plan for this
Related trials for Cardiac Resynchronisation Therapy (CRT)
RecruitingObservational study
BIO|STREAM.CSP Study
Cardiac Pacing, Cardiac Pacemaker
Active, not recruiting
BIO|MASTER.CSP Study
Cardiac Pacing, Artificial, Cardiac Pacemaker, Artificial
Recruiting
Bachmann's Bundle Versus Right Atrial Appendage Pacing
Atrial Fibrillation (AF)
Active, not recruiting
Cardiac Resynchronization Therapy in Previously Untreatable and High Risk Upgrade Patients
Heart Failure
RecruitingObservational study
Non-Invasive Method for Evaluation of Cardiac Resynchronization Therapy
Heart Failure, Pacemaker DDD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Niels Risum Risum, MD, PhD principal investigator
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
michael vinther, MD, PhD principal investigator
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
Berit Philbert study chair
Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark
5 sites in 4 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing HIS or LBBB -CRT and Conventional BiV-CRT in people with Cardiac Resynchronisation Therapy (CRT) and Heart Failure, run by Copenhagen University Hospital, Rigshospitalet at 5 sites in 4 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 10 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Denmark, Finland, Norway, Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Niels Risum, MD, PhD (0045 35456995, niels.risum.01@regionh.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patients with a primary end-point (time frame: From enrollment and a minimum of 2 years or the primary outcome has occurred). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Jul 2026.